Company Overview and News

 
Universal Cables Limited - Change in Company Secretary/Compliance Officer

2018-10-01 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
UNIVCABLES 504212

 
Over 70 stocks hit new 52-week high on BSE; Universal Cables, Globus Spirits jump 5-6%

2018-09-18 moneycontrol
The market trend has reversed this Tuesday morning with the Nifty50 up 12 points and is trading at 11,389 while the Sensex has gained 43 points and is trading at 37,628.
RMGALLOY SANPA 530807 GALLANTT AASHEE 516096 532726 DELTAMAGNT 519319 538634 533104 504286 532651 VRL 500365 GLOBUSSPR REGALIAA SPLIL UNIVCABLES 504212

 
D-Street Buzz: IT stocks gain led by Oracle Financial; sugar stocks continue to rally, RIL drags

2018-09-17 moneycontrol
The Indian stock market have extended the morning loses and are trading well in the red this Monday afternoon with the Nifty50 down 102 points and is trading at 11,412 while the Sensex is trading lower by 391 points at 37,699.
GRASIM IOC 500408 SUZLON 500325 BRTQY TCHQY 532755 SONATSOFTW 532480 500696 BJJQY BRITANNIA SUEL RLNIY 504212 SBAZ GRSJY 524804 UNITDSPR ALBK YYBKY 530965 532667 TECHM 532432 BAJFINANCE TATASTEEL TATLY UQNTY 500300 500825 AUROPHARMA 533271 GODREJIND RELIANCE 512573 HINDUNILVR ASHOKA 532221 500470 RIGD SAKHTISUG UNIVCABLES 500034 YESBANK UBNC AVANTI 532648 GRSXY TTST ARBQY TATAELXSI 507315 500164

 
D-Street Buzz: PSU banks drag as BoB falls 2%; Weak rupee helps IT stocks gain led by Mindtree

2018-09-17 moneycontrol
The Indian stock market are trading on a weak note this Monday morning with the Nifty50 down 110 points and is trading at 11,404 while the Sensex is trading lower by 361 points at 37,729.
IOC 500325 500820 500547 533271 RELIANCE TCHQY 532538 ASHOKA 532755 ASIANPAINT 535789 505200 532461 INOXWIND RIGD UCLQY JSL EICHERMOT UNIVCABLES RLNIY 504212 SBAZ ECQRY UBNC BPCL 532508 IDKQY CANFINHOME UCLQF 511196 530965 ULTRACEMCO TECHM IBULHSGFIN PNJZY BRQPY PNB HINDPETRO 500104 539083

 
D-Street Buzz: IT, pharma stocks gain on weak rupee led by Infosys, Dr Reddy#39;s Labs; Infosys, ITC at new 52-week high

2018-08-31 moneycontrol
The Indian market after opening flat has managed to move higher this Friday morning with the Nifty50 up 47 points at 11,724 while the Sensex is trading higher by 127 points at 38,817.
AMKD 500408 BHRYY AUROPHARMA GODREJIND PQRTY TCHQY PRMQY AMTEKAUTO ICLQY 532832 532755 CADILAHC 532321 534816 INFRATEL INDIACEM UNIVCABLES 504212 524804 PETRONET 532822 530005 PEL CDLYY 532522 TECHM ARBQY IDEA TATAELXSI 500302 520077 500164 IBREALEST

 
Universal Cables Limited - Shareholders meeting

2018-07-31 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
UNIVCABLES 504212

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...